Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers

被引:5
作者
Kannan, M
Ahmad, S
Ahmad, F
Kale, S
Hoppensteadt, DA
Fareed, J
Saxena, R
机构
[1] All India Inst Med Sci, Dept Haematol, New Delhi 110029, India
[2] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA
[3] Florida Hosp, Inst Canc, Orlando, FL USA
关键词
heparin-induced thrombocytopenia; heparin-PF4; antibodies; laboratory tests; inflammatory markers; Asian-Indian subjects;
D O I
10.1097/01.mbc.0000178829.31902.0a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Occurrence of heparin-induced thrombocytopenia (HIT) was investigated for 33 Indian patients undergoing cardiovascular surgery who received unfractionated heparin (UFH). Platelet counts were performed prior to the initiation of UFH therapy and 5-16 days post therapy. Heparin-induced platelet aggregation, C-14-serotonin release assay, and enzyme-linked immunosorbent assay (ELISA) tests were performed in all the patients to detect the antibodies formed against the complex of heparin and platelet factor 4 (HPF4). Levels of inflammatory markers/mediators such as CD40 ligand (CD40L) and C-reactive protein (CRP) were also measured in the patient plasmas utilizing ELISA tests. Based on clinical observations and laboratory diagnoses, five patients (15%) were considered to have confirmed HIT. Despite wide variations in the titers of inflammatory markers, patients who tested ELISA-positive for HPF4 antibodies showed markedly elevated levels of both soluble CD40L and C-reactive protein. Most strikingly, the 14 C-serotonin release assay-positive patients showed up to a 10-fold increase in the level of CD40L. It is concluded that approximately 15% Asian-Indian patients receiving UFH during cardiovascular surgery develop functional HPF4 antibodies, which are associated with the increased levels of inflammatory markers/mediators in this catastrophic HIT syndrome.
引用
收藏
页码:487 / 490
页数:4
相关论文
共 42 条
  • [31] Platelet Factor 4-Positive Thrombi Adhering to the Ventricles of a Ventricular Assist Device in Patients with Heparin-Induced Thrombocytopenia Type II
    Beiras-Fernandez, A.
    Kanzler, I.
    Michel, S.
    Sadoni, S.
    Kilger, E.
    Beiras, A.
    Kur, F.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (05) : 2013 - 2016
  • [32] Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes
    Krauel, K.
    Fuerll, B.
    Warkentin, T. E.
    Weitschies, W.
    Kohlmann, T.
    Sheppard, J. I.
    Greinacher, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (12) : 2160 - 2167
  • [33] A differentiated approach to assess the diagnostic usefulness of a rapid particle gel immunoassay for the detection of antibodies against heparin-platelet factor 4 in cardiac surgery patients
    Risch, L
    Bertschmann, W
    Heijnen, IAFM
    Huber, AR
    BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (01) : 99 - 106
  • [34] Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis
    Tanhehco, Yvette C.
    Rux, Ann H.
    Sachais, Bruce S.
    TRANSFUSION, 2011, 51 (05) : 1022 - 1029
  • [35] Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients
    Ganzel, Chezi
    Rowe, Jacob
    Raveh, David
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2014, 38 (03) : 314 - 320
  • [36] Laboratory testing for platelet factor 4 antibodies: differential utility for diagnosis/exclusion of heparin induced thrombocytopenia versus suspected vaccine induced thrombotic thrombocytopenia
    Favaloro, Emmanuel J.
    Pasalic, Leonardo
    Henry, Brandon
    Lippi, Giuseppe
    PATHOLOGY, 2022, 54 (03) : 254 - 261
  • [37] A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis
    Padmanabhan, Anand
    Jones, Curtis G.
    Curtis, Brian R.
    Bougie, Daniel W.
    Sullivan, Mia J.
    Peswani, Namrata
    McFarland, Janice G.
    Eastwood, Daniel
    Wang, Demin
    Aster, Richard H.
    CHEST, 2016, 150 (03) : 506 - 515
  • [38] Relevance of anti-platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic
    Gendron, Nicolas
    Helley, Dominique
    Thaler, Johannes
    Faille, Dorothee
    Le Beller, Christine
    Gruest, Maxime
    Hadjadj, Jerome
    Philippe, Aurelien
    Zeco, Faris
    Courbebaisse, Marie
    Darnige, Luc
    Amara, Wafa
    Calmette, Leyla
    Parfait, Beatrice
    Auditeau, Claire
    Chocron, Richard
    Khider, Lina
    Mauge, Laetitia
    Espitia, Olivier
    Friedlander, Gerard
    Ajzenberg, Nadine
    Lebeaux, David
    Planquette, Benjamin
    Sanchez, Olivier
    Diehl, Jean-Luc
    Lillo-Le Louet, Agnes
    Terrier, Benjamin
    Smadja, David M.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)
  • [39] Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes
    Mascelli, MA
    Deliargyris, EN
    Damaraju, LV
    Barnathan, ES
    Califf, RM
    Simoons, ML
    Sane, DC
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2005, 18 (03) : 171 - 175
  • [40] Antibodies to Platelet Factor 4/Heparin are Associated with Elevated Endothelial Cell Activation Markers in Patients with Acute Coronary Ischemic Syndromes
    Mary Ann Mascelli
    Efthymios N. Deliargyris
    Lakshmi V. Damaraju
    Elliot S. Barnathan
    Robert M. Califf
    Maarten L. Simoons
    David C. Sane
    Journal of Thrombosis and Thrombolysis, 2004, 18 : 171 - 175